Efficacy and safety of commercialized fecal microbiota transplant for the treatment of recurrent Clostridioides difficile infection

Infect Dis Health. 2023 Feb;28(1):71-73. doi: 10.1016/j.idh.2022.06.002. Epub 2022 Jul 21.

Authors

Usha Yendrapalli¹, Jonathan Edwards², Madeline Belk², Taylor Steuber³, Ali Hassoun⁴

Affiliations

¹ Huntsville Hospital, Hospitalist, Huntsville, AL, USA. Electronic address: ushachowdhary.y@gmail.com.
² Huntsville Hospital, Department of Pharmacy, Huntsville, AL, USA.
³ Auburn University Harrison College of Pharmacy, Department of Pharmacy Practice, Huntsville, AL, USA.
⁴ Alabama Infectious Diseases Center, Huntsville, AL, USA.

PMID: 35871158
DOI: 10.1016/j.idh.2022.06.002

No abstract available

Keywords: Clostridioides difficile; Commercialized FMT; Fecal microbiota transplant.

Publication types

Letter

MeSH terms

Clostridium Infections* / therapy
Fecal Microbiota Transplantation*
Feces
Humans